Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Interest & Investment Income (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Interest & Investment Income data on record, last reported at $5.6 million in Q4 2022.

  • For Q4 2022, Interest & Investment Income rose 10862.75% year-over-year to $5.6 million; the TTM value through Dec 2022 reached $11.2 million, up 5110.75%, while the annual FY2025 figure was $16.4 million, 35.76% down from the prior year.
  • Interest & Investment Income reached $5.6 million in Q4 2022 per AVIR's latest filing, up from $4.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.6 million in Q4 2022 and bottomed at $7000.0 in Q3 2020.
  • Average Interest & Investment Income over 3 years is $954000.0, with a median of $55000.0 recorded in 2020.
  • Peak YoY movement for Interest & Investment Income: increased 1.75% in 2021, then skyrocketed 10862.75% in 2022.
  • A 3-year view of Interest & Investment Income shows it stood at $9000.0 in 2020, then soared by 466.67% to $51000.0 in 2021, then surged by 10862.75% to $5.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $5.6 million in Q4 2022, $4.4 million in Q3 2022, and $1.1 million in Q2 2022.